

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

MHCC97-H

RRID:CVCL_4972

Type: Cell Line

Proper Citation

RRID:CVCL_4972

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4972

Proper Citation: RRID:CVCL_4972

Description: Cell line MHCC97-H is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:11819844](#), [PMID:15048980](#), [PMID:15146329](#), [PMID:23505090](#), [PMID:25690035](#), [PMID:25886575](#), [PMID:31063779](#), [PMID:31378681](#), [PMID:32884988](#)

Comments: Karyotypic information: Has lost chromosome Y., Characteristics: High metastatic potential (PubMed=11819844)., Population: Chinese., Part of: Liver Cancer Model Repository (LIMORE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MHCC97-H

Synonyms: MHCC 97-H, MHCC-97H, MHCC97H, MHCC 97-High metastatic

Cross References: BTO:BTO_0004169, cancercellines:CVCL_4972, ChEMBL-Cells:ChEMBL4295459, ChEMBL-Targets:ChEMBL4296470, GEO:GSM501782, GEO:GSM936771, GEO:GSM1374675, GEO:GSM2551579, LIMORE:MHCC97H, PRIDE:PXD000529, PRIDE:PXD000533, PRIDE:PXD000535, PRIDE:PXD002453, PRIDE:PXD005291, PubChem_Cell_line:CVCL_4972, Wikidata:Q54905533

ID: CVCL_4972

Hierarchy: cvcl_4971

Record Creation Time: 20220427T220806+0000

Record Last Update: 20260905T181142+0000

Ratings and Alerts

No rating or validation information has been found for MHCC97-H.

No alerts have been found for MHCC97-H.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 569 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Xu M, et al. (2026) UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β -Catenin-Driven Hybrid EMT and NK Cell Evasion. *Cancer research*, 86(13), 3213.

Shen Z, et al. (2026) Plasmin promotes hepatocellular carcinoma invasion and metastasis via CXCR4-mediated activation of PI3K/AKT/mTOR signaling. *Oncogene*, 45(19), 1815.

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. *Cancer research communications*, 6(1), 178.

Zhu K, et al. (2026) Targeting the Notch1-YY1-ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8⁺ T-Cell-Driven Cancer Cell Pyroptosis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(7), e12845.

An X, et al. (2026) MAPRE2 is associated with macrophage-enriched innate immune dysregulation and malignant phenotypes in hepatocellular carcinoma. *Frontiers in immunology*, 17, 1849407.

Gu Y, et al. (2026) Sunitinib induces immunogenic cell death through eIF2 γ phosphorylation to potentiate immunotherapy in HCC. *iScience*, 29(4), 115378.

Peng Z, et al. (2026) Master Regulator SMC1A, Stabilized by N6-Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer-Promoter Interaction of Nestin. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(43), e75616.

Qiu W, et al. (2026) An SLCO2B1 mRNA Isoform Acts as a Noncoding RNA to Drive Cancer Progression by Triggering Protein Biosynthesis. *Cancer research*, 86(13), 3142.

Yu X, et al. (2026) Enzyme-responsive 612-AYR nanoparticles for targeted inhibition of B4GALT3-mediated ITGB1 glycosylation in hepatocellular carcinoma. *British journal of pharmacology*, 183(16), 4989.

Wang Y, et al. (2026) NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin. *iScience*, 29(1), 114488.

Guo Z, et al. (2026) RASGEF1B suppresses hepatocellular carcinoma through the ALDH7A1/Betaine/SNAI1 metabolic/epigenetic axis. *Journal of translational medicine*, 24(1).

Zhang R, et al. (2026) TRMT6-Mediated m1A Modification of CDK9 mRNA is a Dual-Pronged Pathogenic Driver for HBV-Related Hepatocellular Carcinoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(39), e14172.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

Sun Z, et al. (2026) Constitutive AMPK activation prevents hepatocellular carcinoma development through inhibition of HNF4 α activity. *Science advances*, 12(15), eaea8017.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.

Chen Z, et al. (2025) Exon Skipping of Ste20-Like Kinase Enhances Glycolysis and Tumor Progression by Activating Enolase 1-Mediated Phosphoenolpyruvate Production. *Cancer research*, 85(20), 3930.

Dong Z, et al. (2025) The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination. *Experimental & molecular medicine*, 57(10), 2317.

Yeung CLS, et al. (2025) Identification of molecular markers and exploration of the oncogenic role of exomeres in hepatocellular carcinoma. *Cell reports*, 44(11), 116460.

Li H, et al. (2025) CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL/RPS transcription. *Nature communications*, 16(1), 7409.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. *Frontiers in immunology*, 16, 1539396.